Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 125

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 125
---
 if they also mature into
actual patents. The product covered by WO 2017/103924 uses a ready–for–use formulation technology which is employed in the
final product. WO 2017/103924 also covers a process of manufacturing of GelrinC that avoids the use of acetone, which may become forbidden
under advanced guidelines for products introduced into the body. Therefore, we believe that upon approval in different territories, additional
patents could provide the Company with sufficient protection from completion even after the expiration dates of the basic patent estate.

GelrinC

The Gelrin technology utilizes
a conjugate of denatured fibrinogen and polyethylene glycol and the intended clinical use of this product is to treat focal cartilage
injuries. These specific conjugate molecules are disclosed and claimed in the earliest patent family of the Company derived from WO 2005/061018,
which are nominally due to expire in December 2025. In various countries, patent term extension or supplementary protection certificates
are available upon receipt of marketing approval to prolong the period of exclusivity of a new medical product. The earliest patent family
of the Company derived from WO 2005/061018 includes patents Nos. US 8,007,774, US 8,858,925, US 9,120,872 and EP 1870115, which are detailed
in the table below.

While the first family of
patents form the “basic patent estate” covering the current products of the Company, diligent efforts have been made by the
Company to cover improvements and alternatives. Our “basic patent estate” has expiration date in December 2025. Although
the patents included in this “basic patent estate” are close to expiring, such patents only cover certain components in the
Company’s products. Our additional subsequently granted patents provide supplementary protection, as well as the latest pending
patent applications which cover subsequent improvements in the Company’s products and processes. Furthermore, regulatory approval,
when obtained, will yield certain types of non-patent exclusivities that can maintain the Company’s advantage even after expiration
of the earlier “basic patent estate”.

<div align='center'>77</div>

We also have additional subsequent
patents that we believe could prevent competitors from entering the market when patents directed to the specific conjugate molecules
expire. The additional patents are directed to manufacturing processes, formulations and other important technologies and serve to support
and extend patent protection beyond the earliest patents